拟2.37亿元控股世之源 申联生物押宝创新药

Core Viewpoint - Shenyuan Biological plans to acquire a controlling stake in Yangzhou Shizhi Source Biotechnology Co., Ltd. to expand into the innovative drug business, focusing on both human pharmaceuticals and animal health, despite facing ongoing net profit losses [1][3]. Group 1: Acquisition Details - The company intends to use 237 million yuan of its own and self-raised funds to gain control of Shizhi Source through its subsidiary, Shanghai Bentianc Biopharmaceutical Co., Ltd. [1] - The acquisition involves a payment of 31.44 million yuan for a portion of Shizhi Source's registered capital and an additional investment of 206 million yuan for new registered capital, resulting in a 40.65% stake [1]. - An employee stock ownership platform will also invest 79.96 million yuan for a 10.35% stake, leading to a combined 51% ownership by Shenyuan and its partners [1][2]. Group 2: Business Transition - This acquisition marks a significant shift for Shenyuan from the veterinary bioproducts sector to a dual focus on human pharmaceuticals and animal health [2][3]. - Shizhi Source is engaged in the development of innovative drugs, holding rights to three drugs in clinical research targeting viral infections and allergic immune responses [2]. - The company aims to leverage synergies in biopharmaceutical technology and production processes post-acquisition to enhance its market position [2]. Group 3: Financial Performance and Risks - Shenyuan is projected to report a net loss of approximately 20 million yuan in 2025, indicating a continued decline in profitability over the past four years [3][4]. - The acquisition may increase financial pressure due to Shizhi Source's ongoing clinical trials and research costs, which will be reflected in Shenyuan's consolidated financial statements [4]. - Shizhi Source is currently not profitable, with projected losses of 15.65 million yuan and 12.94 million yuan for 2024 and 2025, respectively [4].